Search the Newsreel

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Ardelyx (ARDX) Is Down 19.1% After ESOP Shelf Filing And Higher 2026 Product Revenue Guidance

Ardelyx (ARDX) experienced a 19.1% stock drop following a US$36 million shelf registration for an ESOP and its Q2 earnings report. Despite a net loss, the company raised its 2026 IBSRELA revenue guidance to US$350–370 million, while reiterating XPHOZAH revenue expectations. This move signals …

Ardelyx Q2 revenue up 31% but guidance cut due to payer issues, hold rating maintained

Ardelyx reported a 31% year-over-year revenue increase in Q2, driven by strong demand for IBSRELA and XPHOZAH. However, the company cut its revenue guidance to $350-$370 million due to "payer friction" limiting near-term growth. Management is working to address access challenges, and the company …

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story (NASDAQ:ARDX)

Ardelyx, Inc. maintains a "hold" rating due to near-term execution uncertainty despite strong demand for IBSRELA and XPHOZAH. Q2 revenue growth was significant, but payer friction led to a guidance cut, prompting management to enhance reimbursement teams, optimize pharmacy networks, and expand the sales …

Ardelyx, Inc. (ARDX) interactive stock chart

This page provides an interactive stock chart and financial information for Ardelyx, Inc. (ARDX) on Yahoo Finance. It displays real-time stock prices, after-hours trading data, and a list of recent news articles related to the company's financial performance and stock analysis. The content also …

Is Ardelyx (ARDX) Undervalued Following Q2 Results And Updated Product Guidance?

Ardelyx (ARDX) is under pressure despite reporting higher Q2 2026 revenue and a narrower net loss, with its stock down significantly in recent months. However, analysts suggest the company is undervalued, with a consensus price target of $16.33 against a current price of $4.00, …

Ardelyx (ARDX): Millennium entities and Israel Englander report 5.7% stake in 13G/A

Investment entities affiliated with Millennium, including Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, have reported a 5.7% beneficial ownership stake in Ardelyx, Inc. This disclosure, made via a Schedule 13G/A filing, indicates shared voting and dispositive power over 14,200,773 shares. …

HC Wainwright Estimates Ardelyx's Q3 Earnings (NASDAQ:ARDX)

HC Wainwright has lowered its Q3 2026 EPS estimate for Ardelyx (NASDAQ:ARDX) to a loss of $0.06 per share, down from a projected profit of $0.05, while maintaining a "Buy" rating and a $13 price target. This adjustment follows Ardelyx's Q2 earnings report, where …

Ardelyx (ARDX) Is Down 19.7% After Raising IBSRELA Revenue Guidance And Narrowing Losses

3 High Growth Stocks With Healthy Balance Sheets Retail Investors May Be Missing

This article identifies three high-growth stocks with healthy balance sheets that retail investors might be overlooking: Ardelyx (ARDX), Dutch Bros (BROS), and Unity Software (U). These companies are highlighted for their strong projected earnings growth while maintaining solid financial positions, according to an analysis …

Unity Stock And 2 High Growth Picks Worth Watching Now

This article identifies three high-growth potential stocks—Ardelyx (ARDX), Dutch Bros (BROS), and Unity Software (U)—that are worth watching due to their solid earnings growth expectations and balance sheet profiles, despite current market uncertainties driven by inflation. Each company is analyzed for its operations, market …

Citigroup Lowers Ardelyx (NASDAQ:ARDX) Price Target to $11.00

Citigroup has lowered its price target for Ardelyx (NASDAQ:ARDX) from $14.00 to $11.00 but maintained a "buy" rating, suggesting a significant upside. Despite this, other analysts have also recently adjusted their price targets, and the company's latest earnings report showed revenue growth but missed …

3 Financially Strong Penny Stocks Worth A Closer Look

This article identifies three financially strong penny stocks – Ardelyx (ARDX), Alkane Resources (ASX:ALK), and Taboola.com (TBLA) – that warrant further research. These companies were filtered using a "Financially Fit Penny Stocks" screener, highlighting their resilience amidst market uncertainties. Each profile discusses the company's …

Ardelyx, Inc. Stock 12‑Month Price Target Cut to $13, Implies 167% Upside

Ardelyx, Inc.'s stock 12-month price target has been reduced from $16.3 to $13 by analysts, though this still suggests a 167% potential upside based on its recent closing price. Despite the target cut, the consensus rating from 11 analysts remains a "Buy," with no …

Ardelyx (ARDX) Stock Slides As Payer Friction Clouds Growth Path

Ardelyx stock dropped 17.9% to US$4, extending a three-month slide after Q2 product revenue reached US$118 million, primarily from IBSRELA. The company faces challenges including lowered 2026 IBSRELA guidance due to payer access hurdles and confirmed Medicare bundling for XPHOZAH, impacting long-term growth targets. …

ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%?

Ardelyx (ARDX) Posts Record Revenue, Is The Stock Still 70% Undervalued?

Ardelyx falls on lower projected Ibsrela sales, Q2 misses

[Second Quarter Q2 Profits Stock Trading Chart 3D Background] filo * Ardelyx (ARDX [https://seekingalpha.com/symbol/ARDX]) is down ~13% in Friday morning trading after lowering [https://seekingalpha.com/news/4628428-ardelyx-gaap-eps-of-0_07-misses-by-0_01-revenue-of-120_8m-misses-by-0_84m] full-year revenue expectations for its irritable bowel syndrome treatment Ibsrela (tenapanor). * The company now expects 2026 sales of $350M-$370M, …

Ardelyx (NASDAQ:ARDX) Hits New 1-Year Low After Earnings Miss

Ardelyx Inc (ARDX) (Q2 2026) Earnings Call Highlights: Record Revenue of $118M Driven by Strong ...

Ardelyx Inc (ARDX) reported record quarterly revenue of $118 million in Q2 2026, a 31% year-over-year increase, fueled by strong demand for both Ibsrela and Xphozah. Despite this growth, the company lowered its full-year 2026 Ibsrela revenue guidance to $350-$370 million due to significant …

Ardelyx (NASDAQ:ARDX) Announces Quarterly Earnings Results

Ardelyx (ARDX) Reports Q2 Loss, Lags Revenue Estimates

Ardelyx (ARDX) reported a Q2 loss of $0.07 per share, which missed the Zacks Consensus Estimate of a $0.05 loss, and revenues of $120.88 million, falling short of estimates by 2.27%. The company's shares have underperformed the market year-to-date, and its unfavorable estimate revisions …

Ardelyx Inc earnings missed by $0.04, revenue fell short of estimates

Ardelyx Inc (NASDAQ: ARDX) reported a second-quarter EPS of $-0.070, missing the analyst estimate of $-0.030 by $0.04. The company's revenue for the quarter was $118.1M, falling short of the consensus estimate of $125.68M. Ardelyx Inc's stock has decreased by 28.170% in the last …

Earnings call transcript: Ardelyx cuts guidance as stock sinks in Q2 2026

Earnings Flash (ARDX) Ardelyx, Inc. Reports Q2 Revenue $120.9M, vs. FactSet Est of $121.0M

Ardelyx, Inc. (ARDX) reported its Q2 revenue at $120.9 million, slightly below FactSet's estimate of $121.0 million. The company's stock shows a 5-day change of -0.81% and a year-to-date change of -16.47%. Ardelyx is a commercial-stage biopharmaceutical company focused on innovative medicines, including IBSRELA …

Informe de resultados de Ardelyx: recorta previsiones y sus acciones caen en el Q2 2026

Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update

Ardelyx (Nasdaq: ARDX) announced its second quarter 2026 financial results, reporting record combined revenue of $118.1 million, a 31% year-over-year increase, driven by strong performances from IBSRELA and XPHOZAH. Despite increased utilization management from payors affecting IBSRELA revenues, the company updated its full-year 2026 …

Ardelyx (NASDAQ: ARDX) grows IBSRELA, XPHOZAH sales to $211M

ARDX: Q2 2026 revenue up 31% to $118.1M; net loss narrows, guidance updated for market shifts

Ardelyx, Inc. (ARDX) reported a 31% year-over-year revenue increase to $118.1 million in Q2 2026, driven by IBSRELA and XPHOZAH sales. The company's net loss narrowed to $16.7 million, and cash reserves increased to $281.8 million. Ardelyx also updated its full-year 2026 guidance to …

Ardelyx earnings on deck: Can biotech sustain revenue surge?

Ardelyx Inc. is set to report second-quarter earnings, with analysts expecting a narrower loss and significant revenue growth. Investors will focus on the sustainability of its commercial execution for products like IBSRELA and XPHOZAH, alongside the company's path to profitability given recent downward revisions …

Compared to Estimates, Ardelyx (ARDX) Q2 Earnings: A Look at Key Metrics

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx

Faruqi & Faruqi, LLP is investigating potential claims against Ardelyx, Inc. (NASDAQ: ARDX) on behalf of investors who suffered losses exceeding $100,000 between October 31, 2023, and July 1, 2024. The investigation centers on allegations that Ardelyx made misleading statements regarding its intent to …

Renaissance Technologies LLC Sells 522,352 Shares of Ardelyx, Inc. $ARDX

Renaissance Technologies LLC significantly reduced its stake in Ardelyx, Inc. (NASDAQ:ARDX) by selling 522,352 shares, retaining 1.27 million shares valued at $7.6 million. Despite this, institutional investors and hedge funds still own a substantial 58.92% of the company. Ardelyx shares opened at $4.98, below …